Oryzon is a Clinical Stage Biopharmaceutical company and one of the global leaders in the EPIGENETICS pharmaceutical space. We have developed internally a competitive Epigenetic Platform with a first program licensed to ROCHE that validates the platform scientifically and clinically. More precisely, we are leading the Lysine Specific Demethylase-1 (LSD1/KDM1A), a histone demethylase that has been proposed as a target of high interest for oncology, viral diseases and neurodegeneration. Having been one of the first movers, we beneficiate today of a very strong IP position (+20 patent families, with many of them already granted in US).
The company has two therapeutic programs in clinical development, both of them with multiple indication opportunities, and additional assets in preclinical development expected to reach clinical studies soon. The forerunner program (ORY-1001), licensed in 2014 to ROCHE, has finalized Phase I/IIA in Acute Leukemia showing safety, and biological and clinical activity. The second program (ORY-2001) is expected to finish Clinical Phase I in healthy volunteers in 1H2017. The company plans to develop Phase II trials for ORY-2001 in AD, HD and MS. Additional programs are in earlier stages.
Oryzon was founded in 2000 as a spin-off from the University of Barcelona and CSIC in Spain. Born initially as a Functional Genomics company, in 2009 it started its own drug discovery programs in Epigenetics.
Oryzon today is a dynamic and capital efficient company with excellent know-how (40 people). Its headquarters (2200sqm) in Barcelona have world-class labs and offices. The company has also an office in Cambridge, Ma. since 2014.
Oryzon has raised since inception 31M€ in different funding rounds plus +€40M in nonrefundable international and national grants and other types of non-dilutive money. In April 2014, inked a +$500M deal with Roche. To accelerate its growth, the company got public in 2015 in the main market in Spain (ticker ORY.SM).
Organization founded in Spain.